Literature DB >> 18650249

Ibogaine, an anti-addictive drug: pharmacology and time to go further in development. A narrative review.

R Maciulaitis1, V Kontrimaviciute, F M M Bressolle, V Briedis.   

Abstract

Ibogaine is an indole alkaloid derived from the bark of the root of the African shrub Tabernanthe iboga. Psychoactive properties of ibogaine have been known for decades. More recently, based on experimental data from animals and anectodal reports in human, it has been found that this drug has anti-addictive effects. Several patents were published between 1969 and 1995. The pharmacology of ibogaine is quite complex, affecting many different neurotransmitter systems simultaneously. However, the pharmacological targets underlying the physiological and psychological actions of ibogaine are not completely understood. Ibogaine is rapidly metabolized in the body in noribogaine. The purpose of this article was to review data from the literature concerning physicochemical properties, bio-analytical methods, and pharmacology of ibogaine; this article will be focused on the use of this drug as anti-addictive agent.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18650249     DOI: 10.1177/0960327107087802

Source DB:  PubMed          Journal:  Hum Exp Toxicol        ISSN: 0960-3271            Impact factor:   2.903


  15 in total

1.  Noribogaine, but not 18-MC, exhibits similar actions as ibogaine on GDNF expression and ethanol self-administration.

Authors:  Sebastien Carnicella; Dao-Yao He; Quinn V Yowell; Stanley D Glick; Dorit Ron
Journal:  Addict Biol       Date:  2010-10       Impact factor: 4.280

2.  Plants with Anti-Addictive Potential.

Authors:  Eduardo Luis Konrath; Marcelo Dutra Arbo; Bruno Dutra Arbo; Mariana Appel Hort; Elaine Elisabetsky; Mirna Bainy Leal
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 3.  New directions in the treatment of opioid withdrawal.

Authors:  A Benjamin Srivastava; John J Mariani; Frances R Levin
Journal:  Lancet       Date:  2020-06-20       Impact factor: 79.321

Review 4.  GDNF--a potential target to treat addiction.

Authors:  Sebastien Carnicella; Dorit Ron
Journal:  Pharmacol Ther       Date:  2008-12-24       Impact factor: 12.310

Review 5.  From toxins targeting ligand gated ion channels to therapeutic molecules.

Authors:  Adak Nasiripourdori; Valérie Taly; Thomas Grutter; Antoine Taly
Journal:  Toxins (Basel)       Date:  2011-03-21       Impact factor: 4.546

Review 6.  Biosynthesis and synthetic biology of psychoactive natural products.

Authors:  Cooper S Jamieson; Joshua Misa; Yi Tang; John M Billingsley
Journal:  Chem Soc Rev       Date:  2021-06-21       Impact factor: 60.615

7.  Safety of ibogaine administration in detoxification of opioid-dependent individuals: a descriptive open-label observational study.

Authors:  Thomas Knuijver; Arnt Schellekens; Maarten Belgers; Rogier Donders; Toon van Oosteren; Kees Kramers; Robbert Verkes
Journal:  Addiction       Date:  2021-08-09       Impact factor: 7.256

Review 8.  The anti-addiction drug ibogaine and the heart: a delicate relation.

Authors:  Xaver Koenig; Karlheinz Hilber
Journal:  Molecules       Date:  2015-01-29       Impact factor: 4.411

9.  Noribogaine reduces nicotine self-administration in rats.

Authors:  Qing Chang; Taleen Hanania; Deborah C Mash; Emeline L Maillet
Journal:  J Psychopharmacol       Date:  2015-05-20       Impact factor: 4.153

Review 10.  The iboga enigma: the chemistry and neuropharmacology of iboga alkaloids and related analogs.

Authors:  Rishab N Iyer; David Favela; Guoliang Zhang; David E Olson
Journal:  Nat Prod Rep       Date:  2021-03-04       Impact factor: 13.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.